Placebo Controlled Study of Antibiotic Treatment of Soft Tissue Infection
Information source: University of California, San Francisco
Information obtained from ClinicalTrials.gov on June 20, 2008 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Soft Tissue Infections
Intervention: cephalexin (Drug)
Phase: N/A
Status: Completed
Sponsored by: University of California, San Francisco Official(s) and/or principal investigator(s): David M Young, M.D., Principal Investigator, Affiliation: University of California, San Francisco
Summary
This study is to determine whether antibiotic therapy is needed for patients with non-life
threatening soft tissue infections. Most patients with these soft tissue infections are
presently treated with antibiotics. Many of these infections resolve without proper
antibiotic treatment. Treatment of patients with antibiotics after surgical drainage of an
abscess may not be necessary and indiscriminate use of antibiotics may lead to colonization
by drug-resistant organisms. Subsequent infection by drug resistant organisms may limit the
choice of antibiotics in more complicated infections. A comparison between antibiotic
treatment and no antibiotic treatment in surgically treated, uncomplicated soft tissue
infections is needed to address this very important question.
Clinical Details
Official title: A Placebo Controlled, Randomized, and Blinded Study of Antibiotic Treatment of Patients With Uncomplicated Soft Tissue Infection
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Efficacy Study
Primary outcome: Cure of soft tissue infection.
Detailed description:
The Integrated Soft Tissue Infection Service (ISIS) Clinic at San Francisco General Hospital
treats a large number of patients with soft tissue infections, and our data suggest that
antibiotics may be overused for these infections. Most of these infections are treated by
surgical drainage of an abscess (77%). When microbiologic cultures were performed, 88% of the
abscesses were infected with Staphylococcus aureus (S. aureus), and 55% of the abscesses
contained methicillin-resistant Staphylococcus aureus (MRSA). Recently, the high prevalence
of MRSA infection has been documented in San Francisco and throughout the country. Presently,
most patients are treated with antibiotics after drainage of the abscess. Our retrospective
analysis found that 60% of these infections resolved without appropriate antibiotic
treatment. These were patients infected with MRSA who were treated with an antibiotic that
was not active against that organism. This implies that surgical drainage of these abscesses
was probably the important treatment and antibiotic treatment was probably not necessary.
Unnecessary use of antibiotics has adverse consequences. Some patients have allergic
reactions to antibiotics. Patients can develop serious gastrointestinal infections from
antibiotic use. Antibiotics are costly. But most importantly, overuse of antibiotics may be
the significant factor in the spread of antibiotic resistant organisms. The increased
prevalence of MRSA has made it extremely difficult to treat patients with appropriate
antibiotics in life threatening infections (i. e. bacterial endocarditis, osteomyelitis, and
necrotizing soft tissue infections).
The experience in the ISIS Clinic has brought into question our present practice of
antibiotic use in patients with surgically managed abscesses. Many surgeons practicing in the
ISIS clinic believe that antibiotics have little or no effect on the clinical course of these
uncomplicated infections. Elimination of antibiotic use for these uncomplicated infections
would certainly simplify care for these patients. It is even possible that decreased
antibiotic use may decrease the prevalence of MRSA colonization in this population. However,
decreased prevalence of MRSA colonization will not be specifically addressed in this limited
study. A randomized, prospective and blinded trial comparing standard antibiotic treatment
with no treatment should help determine whether antibiotics are really needed for these
infections.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- 1. Patients must have a complicated skin or skin-structure infection that meets
disease diagnostic criteria (severity, definition of complicated, and disease).
SEVERITY: Complicated soft tissue infections must be of sufficient severity to anticipate
five or more days of antibiotic therapy.
DEFINITION OF COMPLICATED (one or more of the following criteria must be met): Infection
requires(ed) significant surgical intervention (such as debridement of devitalized tissue,
drainage of abscess, removal of foreign body implicated in infection) at the time of
enrollment.
DISEASE: Major Abscess (no open wound). The patient must have all of the following: i)
Acute onset within seven days prior to enrollment. ii) Purulent drainage or purulent
aspirate. iii) Erythema, induration (2 cm in diameter), or tenderness. iv) Evidence of
loculated fluid by physical examination, blind aspiration, or ultrasound that requires
intervention (such as aspiration, incision and drainage, excision) at the time of
enrollment.
2. A culture must be obtained at the time of enrollment. 3. Patients must be at least 18
years of age. 4. The patient must sign and date a Committee on Human Research-approved
informed consent form.
Exclusion Criteria:
1. Any of the following conditions:
1. Patients unlikely to survive through the treatment period and evaluations.
2. Conditions such as toxic shock syndrome or toxic-like syndrome (Mandell et al.
2000), shock or hypotension (supine systolic blood pressure <80 mmHg) refractory
to fluid or short course pressor challenge (four hours or less) or oliguria
(urine output <20 mL/hr) not responsive to fluid challenge.
3. Incisional wound that extends into visceral compartments.
4. Suspected or proven contiguous bony or joint involvement.
5. Malignant otitis externa.
6. Ischemic ulcers or wounds associated with sever arterial insufficiency or
gangrene.
7. Infection of prosthetic materials or venous catheters that cannot be removed as
part of the treatment of the current infection.
8. Infection of a full-thickness burn wound or burn wound that is >20% total body
area.
2. Surgical/nonsurgical debridement of devitalized tissue, removal of prosthetic
material, incision and drainage, suture removal, percutaneous aspiration, packing,
dressings, or irrigation (including with antibiotics) that cannot be instituted at the
time of enrollment.
3. Any known sensitivity to cephalexin.
4. Patients with renal compromise.
Locations and Contacts
San Francisco General Hospital, San Francisco, California 94115, United States
Additional Information
Starting date: November 2004
Ending date: March 2005
Last updated: September 15, 2005
|